A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

October 28, 2014

Primary Completion Date

April 4, 2016

Study Completion Date

April 4, 2016

Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
DRUG

AZD7624 1.0 mg

Inhaled AZD7624 solution, 11 mg/mL

DRUG

Placebo

Inhaled placebo solution

Trial Locations (41)

1426

Research Site, Ciudad Autónoma de Bs. As.

1818

Research Site, Johannesburg

2001

Research Site, Johannesburg

2193

Research Site, Parktown West

4000

Research Site, San Miguel de Tucumán

4126

Research Site, eManzimtoti

4302

Research Site, Mount Edgecombe

7764

Research Site, Cape Town

10538

Research Site, Larchmont

16508

Research Site, Erie

21224

Research Site, Baltimore

28207

Research Site, Charlotte

28401

Research Site, Wilmington

29340

Research Site, Gaffney

29605

Research Site, Greenville

29732

Research Site, Rock Hill

30310

Research Site, Atlanta

30513

Research Site, Blue Ridge

33013

Research Site, Hialeah

33024

Research Site, Pembroke Pines

33176

Research Site, Miami

44302

Research Site, Akron

45459

Research Site, Dayton

63141

Research Site, St Louis

77339

Research Site, Kingwood

80206

Research Site, Denver

90036

Research Site, Los Angeles

90505

Research Site, Torrance

3465584

Research Site, Talca

4270918

Research Site, Talcahuano

7980378

Research Site, Santiago

8380453

Research Site, Santiago

C1414AIF

Research Site, Buenos Aires

C1425BEN

Research Site, CABA

B1878FNR

Research Site, Quilmes

9401 RK

Research Site, Assen

6419 PC

Research Site, Heerlen

6525 GA

Research Site, Nijmegen

7207 AE

Research Site, Zutphen

L 41

Research Site, Lima

LIMA 21

Research Site, Lima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY